Literature DB >> 17121137

Genetic profiling of a distant second glioblastoma multiforme after radiotherapy: Recurrence or second primary tumor?

Krista A van Nifterik1, Paula H M Elkhuizen, Rob J van Andel, Lukas J A Stalpers, Sieger Leenstra, M Vincent M Lafleur, W Peter Vandertop, Ben J Slotman, Theo J M Hulsebos, Peter Sminia.   

Abstract

OBJECT: In nearly all patients with glioblastoma multiforme (GBM) a local recurrence develops within a short period of time. In this paper the authors describe two patients in whom a second GBM developed after a relatively long time interval at a site remote from the primary tumor. The genetic profiles of the tumors were compared to discriminate between distant recurrence and a second primary tumor.
METHODS: Both patients harboring a supratentorial GBM were treated with surgery and local high-dose radiotherapy. Local control of the disease at the primary tumor site was achieved. Within 2 years, a second GBM developed in both patients, not only outside the previously irradiated target areas but infratentorially in one patient and in the opposite hemisphere in the other. The tumors were examined for the presence of several genetic alterations that are frequently found in GBMs--a loss of heterozygosity at chromosome regions 1p36, 10pl5, 19q13, and 22q13, and at the CDKN2A, PTEN, DMBT1, and TP53 gene regions; a TP53 mutation; and EGFR amplification. In the first patient, genetic profiling revealed that the primary tumor had an allelic imbalance for markers in several chromosome regions for which the second tumor displayed a complete loss. In the second patient, genetic profiling demonstrated the presence of genetic changes in the second tumor that were identical with and additional to those found in the primary tumor.
CONCLUSIONS: Based on the similarities between the genetic profiles of the primary and the second tumors in these patients, the authors decided that in each case the second distant GBM was a distant recurrence rather than a second independent primary tumor.

Entities:  

Mesh:

Year:  2006        PMID: 17121137     DOI: 10.3171/jns.2006.105.5.739

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  5 in total

1.  Mesenchymal migration as a therapeutic target in glioblastoma.

Authors:  Jessie Zhong; Andre Paul; Stewart J Kellie; Geraldine M O'Neill
Journal:  J Oncol       Date:  2010-06-21       Impact factor: 4.375

2.  Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.

Authors:  Thomas Viel; Parisa Monfared; Sonja Schelhaas; Inga B Fricke; Michael T Kuhlmann; Cornel Fraefel; Andreas H Jacobs
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

Review 3.  A comprehensive profile of recurrent glioblastoma.

Authors:  B Campos; L R Olsen; T Urup; H S Poulsen
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

Review 4.  IDH mutations may not preclude distant, trans-tentorial spread in gliomas: a case report and review of the literature.

Authors:  Christopher S Hong; Jason K Hsieh; Nancy A Edwards; Abhik Ray-Chaudhury; Kareem A Zaghloul
Journal:  World J Surg Oncol       Date:  2016-02-24       Impact factor: 2.754

Review 5.  Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era.

Authors:  Augusto Leone; Antonio Colamaria; Nicola Pio Fochi; Matteo Sacco; Matteo Landriscina; Giovanni Parbonetti; Matteo de Notaris; Giulia Coppola; Elena De Santis; Guido Giordano; Francesco Carbone
Journal:  Biomedicines       Date:  2022-08-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.